Skip to main content
Fig. 3 | BMC Urology

Fig. 3

From: RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma

Fig. 3

CD8 + T cell dysfunction in RCC with high-RUNX3 pathway signature (A) Gating strategies of T cells, CD8 + T cells and CD4 + T cells by flow cytometry in ZS-HRRCC cohort. (B-D) Correlation between RUNX3 pathway signature and (B) T cells, (C) CD8 + T cells and (D) CD4 + T cells. P values and ρ, Spearman’s correlation test. (E-F) Gating strategies of (E) GZMB + CD8 + T cells and (F) PD1 + CD8 + T cells by flow cytometry in ZS-HRRCC cohort, and their association with RUNX3 pathway signature. P values and ρ, Spearman’s correlation test. (G) Correlation between RUNX3 pathway signature and IL6, IL10, TGFB1 and MMP9 expression by RNA-sequencing. P values and ρ, Spearman’s correlation test. (H-I) Gating strategies of (H) macrophages and (I) regulatory T cells by flow cytometry in ZS-HRRCC cohort, and their association with RUNX3 pathway signature. P values and ρ, Spearman’s correlation test

Back to article page